Progression-free survival according to detectable disease status by flow cytometry and NGS. Patients were grouped according to whether MRD was detectable (MRD positive) or undetectable (uMRD; <10⁻⁴) in peripheral blood as analyzed by flow cytometry and by response (A) or detectable (MRD positive) or undetectable (uMRD; <10⁻⁴) in bone marrow as analyzed by NGS and by response (B). Response was classified as CR or PR.